Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
Published Date: 13 Dec 2024
Increased factor VIII levels to mild or moderate range, with annualized bleeding rate of zero
Read Full NewsPsychotropics are associated with increased BMI, and users with a high BMI genetic risk score and an unhealthy lifestyle have triple the risk for CVD, new research shows.
Tafasitamab and lenalidomide are likely to be approved with R-CHOP for frontline DLBCL, but with bispecific antibodies on the horizon, the role of the combination is uncertain.
In a phase 3 trial of patients with dedifferentiated liposarcoma, the CDK4/6 inhibitor extended progression-free survival more than sixfold.
A phase 3 trial evaluates a PARP inhibitor or placebo plus an androgen pathway inhibitor to treat men with advanced prostate cancer associated with genetic changes.
In the first phase 3 trial of teclistamab monotherapy, the bispecific antibody was associated with better PFS and OS than standard regimens in relapsed or refractory multiple myeloma.
A phase 3 trial evaluates the safety and efficacy of an investigational bispecific antibody with chemotherapy compared to standard treatment in advanced squamous NSCLC.
In an interim analysis of a randomized phase 2 trial, asandeutertinib improved intracranial response and intracranial PFS vs osimertinib in patients with EGFR-mutated NSCLC with brain metastases.
1.
Key mechanism behind prostate cancer drug resistance reveals potential new treatment strategy
2.
Breast cancer prevention: How nurse practitioners and physician assistants can help
3.
There is a 40% reduction in the risk of 9 cancers with good cardiorespiratory fitness.
4.
Liver cancer survival rates reflect income disparities
5.
In cases of locally advanced, potentially curable pancreatic cancer, a combination of drugs enhances the results of radiation therapy.
1.
Unraveling the Mysteries of Metastasis: Exploring the Latest Advances in Cancer Research
2.
The Miracle of Tenecteplase: How This Drug Is Saving Lives
3.
The Importance of Iron Rich Foods in Preventing and Treating Anemia
4.
Chloride Test in HCC: Diagnostic Utility, Prognostic Role, and Emerging Insights
5.
The Science Behind Imatinib: How It Targets Cancer Cells
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Revolutionizing Treatment of ALK Rearranged NSCLC with Lorlatinib - Part VII
2.
Revolutionizing Treatment of ALK Rearranged NSCLC with Lorlatinib - Part I
3.
Current Scenario of Cancer- Q&A Session to Close the Gap Part II
4.
A Comprehensive Guide to First Line Management of ALK Positive Lung Cancer - Part V
5.
Evolving Space of First-Line Treatment for Urothelial Carcinoma- Case Discussion
Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
To get started please enter your email ID
Join to enhance your clinical skills and gain specialized in-depth medical knowledge